Art. -Nr.: HY-B1123

Auranofin

(Synonyms: SKF-39162)

45 Cited Publications

Kundenbewertung

Based on 45 publication(s) in Google Scholar

Auranofin (SKF-39162) is a thioredoxin reductase (TrxR) inhibitor with an IC₅₀ of 0.2 μM. Auranofin exhibits antiviral activity against SARS-CoV21, with a CC₅₀ of 4.2 μM for monkey kidney Vero E6 cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.71%
CAS. Nr.: 34031-32-8
Formel: C₂₀H₃₄AuO₉PS
Molecular Weight:678.48

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Auranofin Chemical Structure

CAS. Nr.: 34031-32-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (45)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 0.2 μM (TrxR)^[1]

In Vitro

Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a number of other diseases including cancer, neurodegenerative disorders. Auranofin induces apoptosis in cells through a Bax/Bak-dependent mechanism associated with selective disruption of mitochondrial redox homeostasis in conjunction with oxidation of Prx3^[1].
Auranofin inhibits proliferation and survival of SKOV3 cells in a dose- and time-dependent manner. Auranofin treatment activates the pro-apoptotic caspase-3, increases protein levels of apoptosis-inducing proteins Bax and Bim and reduces the expression of the anti-apoptotic mediator Bcl-2 in SKOV3 cells^[2].
Auranofin is a lipophilic gold compound with anti-inflammatory and immunosuppressive properties. Auranofin inhibits the cell growth and induction of mitochondrial apoptosis in PC3 human prostate cancer cells. Treatment with auranofin significantly inhibits cell viability with an IC₅₀ value of 2.5 μM after 24 h^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Prophylactic treatment of adjuvant-induced arthritis rats with auranofin results in a slight reduction in paw edema, a complete normalization of the depressed IL-2 production, and a reduction of the elevated IL-1 production, but has no effect on the depressed IL-3 production^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 34031-32-8
Appearance Solid
Molecular Weight 678.48
Formel C₂₀H₃₄AuO₉PS
Color White to off-white
SMILES

CC(O[C@@H]([C@@H]([C@H]1COC(C)=O)OC(C)=O)[C@H]([C@@H](O1)[S-][Au+][P](CC)(CC)CC)OC(C)=O)=O
Synonyms

SKF-39162
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (45)

All WBHistological Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nature

Catabolism of extracellular glutathione supplies cysteine to support tumours. [Abstract]

2026 May;653(8115):933-941. PMID: 41851454
Nature

C-terminal amides mark proteins for degradation via SCF-FBXO31. [Abstract]

2025 Feb;638(8050):519-527. PMID: 39880951

Auranofin purchased from MedChemExpress. Usage Cited in: Nature. 2025 Feb;638(8050):519-527. [Abstract]

Co-IP analysis of FBXO31 and endogenous clients as in g for cells treated with H2O2 (20 min, 200 µM), menadione (2 h, 10 µM), or Auranofin (2 h, 10 µM).
Nat Aging

TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation. [Abstract]

2024 Feb;4(2):185-197. PMID: 38267705

Auranofin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Feb;4(2):185-197. [Abstract]

Mice were injected intraperitoneally once every 3 days with 5 mg/kg Auranofin in solvent for 7 times. Images of immunostaining for NLRP3 in the ovary tissues from young (4 months) and aged mice (22 months) with or without Tri-1 and auranofin treatments were obtained.
Nat Microbiol

Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. [Abstract]

2020 Nov;5(11):1439-1448. PMID: 33028965
Nat Commun

Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. [Abstract]

2025 Sep 2;16(1):8181. PMID: 40897711

Auranofin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 2;16(1):8181. [Abstract]

Cell viability in PC9 and A549 cells treated with RSL3 for 6 h or IKE for 24 h following pre-treatment with 1 μM Auranofin, PX-12, or conoidin A for 6 h was measured.
Nat Commun

SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis. [Abstract]

2024 Aug 30;15(1):7522. PMID: 39215042
Nat Commun

Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin. [Abstract]

2020 Oct 16;11(1):5263. PMID: 33067430
Cell Death Differ

SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC. [Abstract]

2020 Mar;27(3):1086-1104. PMID: 31367013
Adv Sci (Weinh)

Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. [Abstract]

2024 Mar;11(9):e2304939. PMID: 38115765
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Redox Biol

Ferroptosis in acute liver Failure: Unraveling the hepcidin-ferroportin axis and therapeutic interventions. [Abstract]

2025 May 8:84:103657. PMID: 40393152
Redox Biol

TrxR1 is involved in the activation of Caspase-11 by regulating the oxidative-reductive status of Trx-1. [Abstract]

2024 Sep:75:103277. PMID: 39059206
Redox Biol

Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo. [Abstract]

2020 Sep;36:101652. PMID: 32750669

Auranofin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2020 Sep;36:101652. [Abstract]

Effect of Auranofin on expression of TXNRD3 and Bcl-2 family members. SK-Hep1OE or SK-Hep1VC cells are treated with various concentrations of Auranofin for 24 h, and immunoblot analysis is performed with the indicated antibodies.
J Hazard Mater

Isobavachalcone confers protection against Cryptococcus neoformans-induced ferroptosis in Caenorhabditis elegans via lifespan extension and GSH-GPX-1 axis modulation. [Abstract]

2025 Mar 18:492:137969. PMID: 40154123
Cancer Biol Med

Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma. [Abstract]

2025 Jun 27:j.issn.2095-3941.2025.0026. PMID: 40579895
NPJ Precis Oncol

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]

2025 Nov 21;9(1):373. PMID: 41272086
Biomed Pharmacother

2023 Apr.
Cell Death Discov

Thioredoxin system dysregulation and calpain activation drive myocardial disulfidptosis via pathological disulfide bonds remodeling. [Abstract]

2026 Jun 19. PMID: 42321161
Cell Death Discov

ChaC1-based drug screenings identify a synergistic lethal effect of auranofin and proteasome inhibitors in hepatocellular carcinoma cells. [Abstract]

2025 Nov 17;11(1):532. PMID: 41249117
Arch Toxicol

Wogonin induces cellular senescence in breast cancer via suppressing TXNRD2 expression. [Abstract]

2020 Oct;94(10):3433-3447. PMID: 32671444
Cell Rep

Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. [Abstract]

2019 Jul 9;28(2):512-525.e6. PMID: 31291585
Antioxidants (Basel)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. [Abstract]

2023 Mar 8;12(3):667. PMID: 36978917
Ecotoxicol Environ Saf

Low-dose arsenite causes overexpression of EGF, TGFα, and HSP90 through Trx1-TXNIP-NLRP3 axis mediated signaling pathways in the human bladder epithelial cells. [Abstract]

2022 Dec 1:247:114263. PMID: 36343453
Eur J Med Chem

Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors. [Abstract]

2023 Jan 5;245(Pt 1):114860. PMID: 36370550
Int J Mol Sci

Lactate Uptake by MCT4 Facilitates Stability and Suppressive Function of Tumor-Infiltrating Regulatory T Cells by Promoting Foxp3 Lactylation. [Abstract]

2026 May 21;27(10):4619. PMID: 42196594
PLoS Pathog

Structural basis for substrate recognition and inhibition of thioredoxin glutathione reductase from Schistosoma japonicum: Implications for antiparasitic development. [Abstract]

2026 Apr 24;22(4):e1014125. PMID: 42030356
Int J Mol Sci

Selenium-Thioredoxin Axis Contributes to Ferroptosis Resistance in Pancreatic Cancer Cells. [Abstract]

2026 Feb 23;27(4):2062. PMID: 41752199
Molecules

Inhibition of Mitochondrial Antioxidant Defense and CDK4/6 in Mesothelioma. [Abstract]

2023 May 27;28(11):4380. PMID: 37298855
Probiotics Antimicrob Proteins

Synergistic Effects of Auranofin and Lysozyme Against Staphylococcus Aureus. [Abstract]

2026 Mar 17. PMID: 41843357
Cancers

Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism. [Abstract]

2019 Jul 3;11(7):931. PMID: 31277230
Antiviral Res

Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity. [Abstract]

2026 Jun:250:106417. PMID: 42025967
Sci Rep

Cysteine-reactive mitigators of small vessel disease-related NOTCH3 mutants. [Abstract]

2026 Mar 20;16(1):14300. PMID: 41862552
Neurochem Res

Schisanhenol Inhibits MPTP/MPP+-Induced Ferroptosis in Dopaminergic Neurons Via Nrf2/TrxR1/GPX4 Pathway against Parkinson's Disease. [Abstract]

2025 Dec 29;51(1):26. PMID: 41460594
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Front Oncol

PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway. [Abstract]

2018 Dec 17:8:611. PMID: 30619751

Auranofin purchased from MedChemExpress. Usage Cited in: Front Oncol. 2018 Dec 17:8:611. [Abstract]

Protein expression of Caspase3/9, Cleaved caspase3/9, Bax, Bcl2, TXNRD1, and PCK1. PCK1-KO hepatoma cells are treated with Auranofin, Sorafenib or Auranofin+Sorafenib as and the proteins are isolated and analyzed by western blotting.
Invest New Drugs

A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer. [Abstract]

2019 Dec;37(6):1166-1176. PMID: 30825105
Vet Comp Oncol

Auranofin Suppresses the Growth of Canine Mammary Tumour Cells and Induces Apoptosis via the PI3K/AKT Pathway. [Abstract]

2024 Dec;22(4):555-565. PMID: 39221701
Res Sq

2026 Jun 15.
bioRxiv

2026 Jan 26.
SSRN

2025 Aug 7.
bioRxiv

Catabolism of extracellular glutathione supplies amino acids to support tumor growth. [Abstract]

2024 Oct 13:2024.10.10.617667. PMID: 39416022
bioRxiv

2024 November 10.
SSRN

2024 May 17.
bioRxiv

2024 May 15.
The Hong Kong Polytechnic University

2023 Aug.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (73.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4739 mL

7.3694 mL

14.7388 mL

5 mM

0.2948 mL

1.4739 mL

2.9478 mL

10 mM

0.1474 mL

0.7369 mL

1.4739 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (3.07 mM); Suspended solution; Need ultrasonic and warming

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

Auranofin is dissolved in DMSO. Cells are treated with auranofin (0, 50, 100, 200 and 400 nM) for 72 h for the dose-dependent response assay and 100 nM of auranofin is added into the wells for 0, 24, 72 and 120 h for the time-dependent response assay. Control cultures are treated with DMSO. Cell viability is measured by the MTT assay^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Rats: Prophylactically, auranofin (6.7 to 15 mg of gold/kg), indomethacin (2 mg/kg) or tragacanth vehicle control were administered orally at daily intervals beginning on the day of adjuvant injection. On days 16 to 17 peritoneal exudate cells or spleen cells from normal or adjuvant-injected rats were isolated and tested^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (805 KB)
- English - EN (805 KB)
- Français - FR (805 KB)
- Deutsch - DE (805 KB)
- Norwegian - NO (805 KB)
- Español - ES (805 KB)
- Swedish - SV (805 KB)
- Italian - IT (805 KB)
- Korean - KR (805 KB)
- Portuguese - PT (805 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Cox AG, et al. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol. 2008 Oct 30;76(9):1097-109. [Content Brief]

[2]. Park SH, et al. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int J Oncol. 2014 Oct;45(4):1691-8. [Content Brief]

[3]. Park N, et al. Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J Toxicol Environ Health A. 2014;77(22-24):1467-76. [Content Brief]

[4]. Lee JC, et al. Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats. J Immunol. 1987 Nov 15;139(10):3268-74. [Content Brief]

[5]. Shuofeng Yuan, et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020 Oct 7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4739 mL	7.3694 mL	14.7388 mL	36.8471 mL
	5 mM	0.2948 mL	1.4739 mL	2.9478 mL	7.3694 mL
	10 mM	0.1474 mL	0.7369 mL	1.4739 mL	3.6847 mL
	15 mM	0.0983 mL	0.4913 mL	0.9826 mL	2.4565 mL
	20 mM	0.0737 mL	0.3685 mL	0.7369 mL	1.8424 mL
	25 mM	0.0590 mL	0.2948 mL	0.5896 mL	1.4739 mL
	30 mM	0.0491 mL	0.2456 mL	0.4913 mL	1.2282 mL
	40 mM	0.0368 mL	0.1842 mL	0.3685 mL	0.9212 mL
	50 mM	0.0295 mL	0.1474 mL	0.2948 mL	0.7369 mL
	60 mM	0.0246 mL	0.1228 mL	0.2456 mL	0.6141 mL

Keywords

Auranofin

45 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Auranofin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Auranofin

Biologische Aktivität

Chemical Information

Publications (45)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Auranofin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Auranofin

Biologische Aktivität

Chemical Information

Publications (45)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Auranofin Related Classifications

HY-B1123 Related Classifications